SCHEMBL10242017

SCHEMBL10242017

Cc1cc(C(=O)N(C)C)ccc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.50
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PDK2 Q15119 2/20 0.46
PDK1 Q15118 2/20 0.46
PDK3 Q15120 1/20 0.46
PDK4 Q16654 1/20 0.46
HSP90AA1 P07900 5/20 0.45
TP53 P04637 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HSP90AB1 P08238 4/20 0.44
PDE10A Q9Y233 1/20 0.42
DYRK1A Q13627 1/20 0.42
DYRK1B Q9Y463 1/20 0.42
HSD17B1 P14061 2/20 0.41
HSD17B2 P37059 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ESR1 P03372 2/20 0.41
ESR2 Q92731 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12051807 0.83 SMN1; SMN2 (0.52) ERN1ALDH1A1HPGDSMN1; SMN2TP53
SCHEMBL9131982 0.83 CA12 (0.56) ERN1ALDH1A1HPGDSMN1; SMN2PDK2
SCHEMBL12217575 0.82 HSP90AA1 (0.43) HPGDHSP90AA1TP53TDP1HSP90AB1
SCHEMBL11516514 0.82 HSP90AA1 (0.50) HPGDSMN1; SMN2PDK2HSP90AA1TP53
SCHEMBL12218608 0.81 ESR1 (0.40) ERN1PDK2PDK1PDK3PDK4
SCHEMBL20056694 0.81 ERN1 (0.68) ERN1HPGDPDK2HSD17B1HSD17B2
SCHEMBL4545228 0.79 HSP90AA1 (0.70) ALDH1A1HPGDSMN1; SMN2HSP90AA1TDP1
SCHEMBL12217576 0.79 PDK2 (0.46) HPGDPDK2HSP90AA1HSP90AB1ESR1
SCHEMBL12218597 0.79 PDK2 (0.46) ALDH1A1PDK2HSP90AA1TP53TDP1
SCHEMBL12218510 0.79 PDK1 (0.44) HPGDPDK1HSP90AA1HSP90AB1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752587-B2 Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use MERCK SHARP & DOHME CORP. (US) 2020-08-25 US disclosed
WO-2017095758-A1 HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2017-06-08 WO disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-8039638-B2 Inhibitors of HIV replication BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-18 US disclosed
US-8039638-B2 Inhibitors of HIV replication BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-18 US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 US disclosed
US-20100069353-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-03-18 US disclosed
US-20100069353-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-03-18 US disclosed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 US disclosed
US-20080311074-A1 Inhibitors against activation of NF-kappaB INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) 2008-12-18 US disclosed
US-20080249071-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2008-10-09 US disclosed
US-20080234233-A1 MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) 2008-09-25 US disclosed
WO-2008067644-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-06-12 WO disclosed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US disclosed
EP-1847263-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-24 EP disclosed
EP-1844766-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-17 EP disclosed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US disclosed
US-20070042997-A1 Medicament for treatment of dermal pigmentation INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311074-A1 Inhibitors against activation of NF-kappaB NFKBIA, IKBKB, RELA ERN1 569/4885ALDH1A1 2096/4885HPGD 240/4885
US-20100069353-A1 INHIBITORS OF HIV REPLICATION RTF2, REV1, CCNT1 ERN1 289/4885ALDH1A1 3455/4885HPGD 1965/4885
US-20080090779-A1 ANTIALLERGIC AGENTS NAT1, EPX, HRH2 ERN1 2620/4885ALDH1A1 364/4885HPGD 80/4885
US-10752587-B2 Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use NR1H2, NR1H3, NR1H4 ERN1 3366/4885ALDH1A1 2553/4885HPGD 1249/4885
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A ERN1 1883/4885ALDH1A1 479/4885HPGD 272/4885
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A ERN1 1918/4885ALDH1A1 563/4885HPGD 238/4885
US-20080249071-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A ERN1 1918/4885ALDH1A1 563/4885HPGD 238/4885
US-20080234233-A1 MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAPT, TFEB, MAOA ERN1 3188/4885ALDH1A1 425/4885HPGD 647/4885
US-20070185110-A1 Antiallergic agents NAT1, EPX, AHR ERN1 2842/4885ALDH1A1 340/4885HPGD 99/4885
US-20070185059-A1 Antiallergic agents NAT1, EPX, AHR ERN1 2799/4885ALDH1A1 362/4885HPGD 103/4885
US-20070042997-A1 Medicament for treatment of dermal pigmentation TYR, XDH, XPA ERN1 4490/4885ALDH1A1 140/4885HPGD 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.